WP-4 In silico tools

WP leaders: Xavier Pepin, Sanofi-Aventis Research and Development and Amin Rostami, University of Manchester

The objectives of WP4 are:

  • Data collection and data management.
  • Set up and establish model quality indicators to account for improvements from the initial gap analysis using current tools and throughout the project to monitor the 

progresses made.
  • Refinement of integrative in silico tools for bioavailability anticipation by developing enhanced physiological data base, new model algorithm and new in vitro inputs in link with WPs 1-3.
  • Development of framework for API formulation type selection and identification of biowaiver (in vitro BE) opportunities based on predictive models.
  • Dissemination and propagation of information related to model based drug development concerning oral absorption.

In essence the objectives proposed within WP4 are intimately linked with the achievements of WPs1-3. Indeed, integrative tools will make use of the measured values for solubility, permeability, and precipitation rate and of the physical models of these, which will come from WP1-3. By iterative approaches, and the testing of several inputs to the models coupled to model refinements, the ultimate aim is to progress in terms of quality of bioavailability anticipation.

Go back to WORK PACKAGES